This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Trospium oral


Tablets containing trospium chloride

Drugs List

  • REGURIN 20mg tablets
  • trospium chloride 20mg tablets
  • Therapeutic Indications


    Symptomatic treatment of urinary urgency, frequency or urge incontinence

    Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (e.g. idiopathic or neurologic detrusor overactivity).



    20 mg twice a day.


    20 mg twice a day.


    Children 12 to 18 years
    20 mg twice a day.

    Patients with Renal Impairment

    Severe renal impairment (creatinine clearance 10 to 30 ml/minute)
    20 mg of daily or every second day.


    Children under 12 years
    Gastrointestinal atony
    Myasthenia gravis
    Narrow angle glaucoma
    Severe gastrointestinal disorder
    Severe hepatic impairment
    Severe ulcerative colitis
    Toxic megacolon
    Urinary retention

    Precautions and Warnings

    Children aged 12 to 18 years
    Frail elderly patients
    Predisposition to glaucoma
    Autonomic neuropathy
    Benign prostatic hyperplasia
    Bladder outflow obstruction
    Congestive cardiac failure
    Gastrointestinal obstruction
    Glucose-galactose malabsorption syndrome
    Hereditary fructose intolerance
    Hiatus hernia
    Ischaemic heart disease
    Lactose intolerance
    Mild hepatic impairment
    Reflux oesophagitis
    Renal impairment - creatinine clearance below 30 ml/minute

    Advise visual disturbances may affect ability to drive or operate machinery
    Contains lactose
    Some formulations contain sucrose
    Some formulations contain wheat starch
    Reassess need for continued treatment at regular intervals of 3-6 months
    May cause heat prostration when used in high environmental temperatures

    Pregnancy and Lactation


    Use trospium chloride with caution in pregnancy.

    At the time of writing no clinical data on human pregnancies exposed to trospium has been located.

    In animal studies, placenta transfer of trospium was seen but did not indicate any direct or indirect adverse effects on pregnancy, embryo or foetal development, parturition, or postnatal development in rats.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use trospium chloride with caution in breastfeeding.

    At the time of writing there is no data to show if trospium is excreted in human breast milk.

    Animal studies have shown that trospium chloride passes in maternal milk, therefore, a risk to the newborn cannot be excluded.

    The UK Drugs in Lactation Advisory Service states that due to the long half-life of trospium chloride there is an increased risk of accumulation in breastfed infants. It also recommends that breastfed infants should be monitored for anticholinergic effects e.g. urinary retention, colic and constipation.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at


    The tablets should be swallowed whole with water before meals (on an empty stomach).

    Advise patient that if side effects affecting their vision occur they should not drive and operate machinery.

    Side Effects

    Abdominal pain
    Chest pain
    Disturbances in accommodation
    Dry mouth
    Impaired vision
    Increase in serum transaminases
    Micturition disorders
    Stevens-Johnson syndrome
    Toxic epidermal necrolysis
    Urinary retention


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2015

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Accessed on 26 October 2015.

    Summary of Product Characteristics: Flotros 20mg film-coated tablets. Galen Limited. Revised July 2015.

    Summary of Product Characteristics: Regurin 20g tablets. Speciality European Pharma. Revised October 2010.

    Summary of Product Characteristics: Uraplex 20g coated tablets. Speciality European Pharma. Revised August 2011.

    UK Drugs in Lactation Advisory Service.
    Available at:
    Last accessed: 26 October 2015

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.